表紙:Lumakras:薬剤臨床の洞察と販売予測(2026年)
市場調査レポート
商品コード
1019445

Lumakras:薬剤臨床の洞察と販売予測(2026年)

Lumakras Drug Clinical Insight & Sales Forecast 2026

出版日: | 発行: KuicK Research | ページ情報: 英文 60 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.50円

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Lumakras:薬剤臨床の洞察と販売予測(2026年)
出版日: 2021年07月15日
発行: KuicK Research
ページ情報: 英文 60 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

がん患者数の増加とがん死亡率の上昇に伴い、がん治療のための新しい治療法の開発が求められています。がん治療の分野で大きな進歩があったにもかかわらず、現在までがんを根治することはできていません。しかし、科学技術の進歩により、医薬品開発プロセスに利用できる潜在的なターゲットが特定されてきました。

その中でも、Kirsten rat sarcoma viral oncogene homolog(KRAS)遺伝子と、その遺伝子ががんの病因や増殖に果たす役割が明らかになったことは、がん治療の恩恵をもたらすものと考えられます。研究者たちによる広範な研究開発の結果、新規のKRAS阻害剤が発見され、希少なALK陽性がんの治療に使用されています。現在のところ、非小細胞肺がんの治療薬として承認されているKRAS阻害剤は1つだけです。

Lumakras(ソトラシブ)は、Amgenが開発した最初のKRAS阻害剤で、2021年5月にFDAから承認されました。Lumakrasは、1日1回の経口処方薬で、他の部分に移転、および手術で除去できない非小細胞肺がん(NSCLC)で、腫瘍にKRAS G12C遺伝子の異常があり、がんに対する少なくとも1回の前治療を受けた成人の患者さんの治療に使用されます。Lumakrasが承認されたことは、がん治療の分野における大きな革命の一つです。

当レポートは、Lumakrasについて調査しており、NSCLCおよび大腸がんをターゲットとした市場機会、薬物動態、用法・用量、特許、価格分析、進行中の臨床試験、世界におけるKRASタンパク質阻害剤の臨床試験、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 Lumakras(ソトラシブ)-最初に承認されたKRAS阻害薬

  • 市場概要
  • 将来の機会

第2章 Lumakras-作用機序

第3章 Lumakras-構造、説明および薬物動態

  • 化学および物理的性質
  • 薬物動態

第4章 NSCLCにおけるLumakrasの役割

第5章 固形腫瘍におけるLumakrasの役割

第6章 Lumakras-商業的側面

  • 概要と特許インサイト
  • 投与量と価格分析

第7章 Lumakras-補足情報

  • 副作用
  • 薬物相互作用
    • Lumakrasに対する他の薬剤の効果
    • 他の薬に対するLumakrasの効果

第8章 Lumakrasの進行中の臨床試験

  • 世界のKRASタンパク質阻害剤の臨床試験
  • 世界のLumakras臨床試験

第9章 地域別の臨床開発動向

  • 米国
  • その他の地域

第10章 KRAS阻害剤の開発に関与する企業

  • Amgen
  • Boehringer Ingelheim
  • Codiak Biosciences
  • Cotinga Pharmaceuticals
  • Eli Lilly
  • Gilead
  • Johnson & Johnson
  • Mirati Therapeutics
  • Merck
  • Moderna
  • Oblique Therapeutics
  • Revolution Medicines
  • Silenseed
図表

List of Figures

  • Figure 1-1: Global - Frequency of KRAS G12C Mutation by Cancer Type (%), 2021 & 2026
  • Figure 1-2: Global - KRAS Mutation by Type (%), 2020
  • Figure 1-3: Global - Estimated KRAS Mutated NSCLC Population for KRAS Inhibitors, 2021 & 2026
  • Figure 1-4: Global - NSCLC Targeting Lumakras Market Opportunity by 5% of Targeted Population (US$ Million), 2021 - 2026
  • Figure 1-5: Global - NSCLC Targeting Lumakras Market Opportunity by 10% of Targeted Population (US$ Million), 2021 - 2026
  • Figure 1-6: Global - NSCLC Targeting Lumakras Market Opportunity by 15% of Targeted Population (US$ Million), 2021 - 2026
  • Figure 1-7: Global - NSCLC Targeting Lumakras Market Opportunity by 20% Targeted Population (US$ Billion), 2021 - 2026
  • Figure 1-8: Global - NSCLC Targeting Lumakras Market Opportunity by 25% Targeted Population (US$ Billion), 2021 - 2026
  • Figure 1-9: Global - Estimated KRAS G12C Mutated Colorectal Cancer Population for KRAS Inhibitors, 2021 & 2026
  • Figure 1-10: Global - Colorectal Cancer Targeting Lumakras Market Opportunity by 5% of Targeted Population (US$ Million), 2021 - 2026
  • Figure 1-11: Global - Colorectal Cancer Targeting Lumakras Market Opportunity by 10% of Targeted Population (US$ Billion), 2021 - 2026
  • Figure 1-12: Global - Colorectal Cancer Targeting Lumakras Market Opportunity by 15% of Targeted Population (US$ Million), 2021 - 2026
  • Figure 1-13: Global - Colorectal Cancer Targeting Lumakras Market Opportunity by 20% Targeted Population (US$ Billion), 2021 - 2026
  • Figure 1-14: Global - Colorectal Cancer Targeting Lumakras Market Opportunity by 25% Targeted Population (US$ Billion), 2021 - 2026
  • Figure 2-1: General Mechanism of KRAS Inhibitors against Cancer
  • Figure 2-2: Targeting Approaches of KRAS Inhibitors
  • Figure 2-3: Mechanism of Lumakras - Direct Targeting of Mutant KRAS
  • Figure 3-1: Structure of Lumakras
  • Figure 4-1: Global - Newly Diagnosed Cases & Deaths Related to Lung Cancer (Million), 2020
  • Figure 4-2: Global - Lung Cancer Incidence by Type (%), 2020
  • Figure 4-3: Impact of KRAS Inhibitor on Lung Cancer
  • Figure 5-1: Global - Frequency of Overall KRAS Mutation & KRAS G12C Mutation (%)
  • Figure 6-1: Lumakras - FDA Approval & Patent Expiration Year
  • Figure 6-2: Lumakras - Price for 240 Tablet Supply & Price Per Unit of 120mg Tablet (US$), July'2021
  • Figure 6-3: Lumakras - Monthly & Annual Treatment Cost (US$), July'2021
  • Figure 6-4: Lumakras - Recommended Initial & Reduced Dose (mg/day)
  • Figure 7-1: Lumakras - List of Adverse Events
  • Figure 8-1: Global - KRAS Protein Inhibitors Clinical Trials by Phase, 2020 -2026
  • Figure 8-2: Global - KRAS Protein Inhibitors Clinical Trials by Country, 2020 -2026
  • Figure 8-3: Global - KRAS Protein Inhibitors Clinical Trials by Company, 2020 -2026
  • Figure 8-4: Global - KRAS Protein Inhibitors Clinical Trials by Indication, 2020 -2026
  • Figure 8-5: Global - KRAS Protein Inhibitors Clinical Trials by Patient Segment, 2020 -2026
  • Figure 8-6: Global - Number of KRAS G12C Inhibitors in Clinical Trial by Phase, July 2021
  • Figure 8-7: Global - KRAS G12C Inhibitors in Clinical Trial by Phase (%), July 2021
  • Figure 8-8: Codebreak 200 Trial - Study Initiation & Expected Completion Year
  • Figure 8-9: Codebreak 105 Trial - Study Initiation & Expected Completion Year
  • Figure 8-10: Codebreak 101 Trial - Study Initiation & Expected Completion Year
目次

"Lumakras Drug Clinical Insight & Sales Forecast 2026" Report Highlights:

  • NSCLC Targeting Lumakras Market Opportunity (US$ Million)
  • Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million)
  • Pharmacokinetics of Lumakras (Sotorasib)
  • Dosage, Patent & Price Analysis
  • Lumakras Ongoing Clinical Trials
  • Global KRAS Protein Inhibitors Clinical Trials

The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management of cancer. Despite huge advancements in the field of cancer therapeutics, there has been no permanent cure of cancer till now. However, the advancement in the field of science and technology has led to the identification of potential targets which can be utilized in drug development process.

The identification of Kirsten rat sarcoma viral oncogene homolog (KRAS) gene as well as its potential role in the pathogenesis and proliferation of cancer has shown to be boon in cancer therapeutics. The extensive research and development by the researchers has led to the discovery of novel KRAS inhibitors which are used in the management of rare ALK positive cancers. Till now, only one KRAS inhibitor has been approved for the management of non-small cell lung cancer.

Lumakras (Sotorasib) is first KRAS inhibitor developed by Amgen and was approved by FDA in May, 2021. Lumakras is a once-daily oral prescription medicine used to treat adults living with non-small cell lung cancer (NSCLC) that has spread to other parts of the body or cannot be removed by surgery, and whose tumor has an abnormal KRAS G12C gene, and who have received at least one prior treatment for their cancer. The approval of Lumakras represents as one of the major revolution in the field of cancer treatment.

Owing to their favorable characteristics in management of NSCLC as well its high specificity and efficacy, it is expected that Lumakras market will witness high growth rates. As per report findings, it is expected that Lumakras market is expected to surpass US$ 1.5 Billion by 2026. This is due to the ability of Lumakras in overcoming the limitations of already conventional cancer therapies. Moreover, the drug Lumakras is not associated with side effects in comparison to conventional cancer treatments and also improved the survival rates in patients.

Although the market is poised to growth in coming years but several factors limits their growth in market. The high cost of cancer therapy is one of the major limiting factors which will restrict the growth of market in coming years. However, increasing initiatives by government and the pharmaceutical companies for the development of favorable reimbursement policies will help in lowering the cost of the therapy, thus reducing financial toxicity on patients.

The global Lumakras market will follow trajectory path during the forecast period owing to the single product approval. In addition to this, researchers are also evaluating the role of Lumakras in other solid tumors as well in combination of other immunotherapeutic drugs, which will drive the growth of market. North America particularly US is expected to dominate the global Lumakras market for next few years owing to increase in prevalence of non-small cell lung cancer and the presence of large pharmaceutical companies which actively indulge in research and development activities.

The report global Lumakras market contains information on the price, dosage and expected sales of the drug in different regions. In addition to this, it also provides information on the safety, efficacy, pharmacokinetics, and pharmacovigilance profile of Lumakras. The report also provides insights on the recent clinical trials undergoing with the drug and predict the future market of the drug at a global level.

Table of Contents

1. Lumakras (Sotorasib) - First Approved KRAS Inhibitor Drug

  • 1.1. Market Overview
  • 1.2. Future Opportunity

2. Lumakras - Mechanism of Action

3. Lumakras - Structure, Description & Pharmacokinetics

  • 3.1. Chemistry & Physical Properties
  • 3.2. Pharmacokinetics

4. Role of Lumakras in NSCLC

5. Role in Lumakras in Solid Tumors

6. Lumakras - Commercial Aspects

  • 6.1. Overview & Patent Insight
  • 6.2. Dosage & Price Analysis

7. Lumakras - Supplementary Information

  • 7.1. Adverse Drug Reactions
  • 7.2. Drug Interaction
    • 7.2.1. Effects of Other Drugs on Lumakras
    • 7.2.2. Effects of Lumakras on Other Drugs

8. Lumakras Ongoing Clinical Trials

  • 8.1. Global KRAS Protein Inhibitors Clinical Trials
  • 8.2. Global Lumakras Clinical Trials

9. Clinical Development Trends by Regions

  • 9.1. US
  • 9.2. Rest of World

10. Companies Involved in Development of KRAS Inhibitors

  • 10.1. Amgen
  • 10.2. Boehringer Ingelheim
  • 10.3. Codiak Biosciences
  • 10.4. Cotinga Pharmaceuticals
  • 10.5. Eli Lilly
  • 10.6. Gilead
  • 10.7. Johnson & Johnson
  • 10.8. Mirati Therapeutics
  • 10.9. Merck
  • 10.10. Moderna
  • 10.11. Oblique Therapeutics
  • 10.12. Revolution Medicines
  • 10.13. Silenseed